skli
2021-07-17
Expected
Moderna Surges to Record High as Vaccine Maker Added to S&P 500<blockquote>随着疫苗制造商加入标普500，Moderna 飙升至历史新高</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":179044650,"tweetId":"179044650","gmtCreate":1626478484770,"gmtModify":1631887912545,"author":{"id":3583042826015243,"idStr":"3583042826015243","authorId":3583042826015243,"authorIdStr":"3583042826015243","name":"skli","avatar":"https://static.tigerbbs.com/cb36785e9f320f479b566e1e20e9c3e3","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","extraTitle":"","html":"<html><head></head><body><p>Expected </p></body></html>","htmlText":"<html><head></head><body><p>Expected </p></body></html>","text":"Expected","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/179044650","repostId":1168174427,"repostType":4,"repost":{"id":"1168174427","kind":"news","pubTimestamp":1626445586,"share":"https://www.laohunote.com/m/news/1168174427?lang=zh_CN&edition=full","pubTime":"2021-07-16 22:26","market":"us","language":"en","title":"Moderna Surges to Record High as Vaccine Maker Added to S&P 500<blockquote>随着疫苗制造商加入标普500，Moderna 飙升至历史新高</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1168174427","media":"Thestreet","summary":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped t","content":"<p>Moderna Inc. (<b>MRNA</b>) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.</p><p><blockquote>现代公司（<b>MRNA</b>) 该疫苗制造商有望下周进入标普500基准市场，周五股价飙升至历史新高。</blockquote></p><p> Moderna will replaceAlexion Pharmaceuticals (<b>ALXN</b>) in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (<b>AZN</b>) in December of last year.</p><p><blockquote>Moderna 将取代 Alexion Pharmaceuticals（<b>阿尔克辛</b>) 在全球最受密切关注的指数中，从 7 月 21 日星期三开盘开始，此前该指数被英国阿斯利康 (AstraZeneca) 以 390 亿美元收购 (<b>阿兹恩</b>）去年12月。</blockquote></p><p> Moderna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.</p><p><blockquote>Moderna 股价在周五早盘交易中上涨 6%，易手至每股 275.92 美元，创历史新高，这将使该股年初至今的涨幅扩大至约 165%，市值约为 1110 亿美元。</blockquote></p><p> Moderna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.</p><p><blockquote>Moderna 于 5 月 6 日公布的第一季度收益为每股 2.84 美元，好于预期，收入升至 19 亿美元。该制药商还将 2021 财年全年疫苗销售预测上调至 192 亿美元左右。</blockquote></p><p> Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.</p><p><blockquote>Moderna 2021 年的基本计划是生产 8 亿剂信使 RNA 疫苗，该疫苗于去年 12 月获得 FDA 紧急批准，目标是“努力在 2021 年尽可能接近 10 亿剂，”班塞尔在 5 月初表示。</blockquote></p><p> \"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"</p><p><blockquote>“来自世界各国政府要求高效 mRNA 疫苗和变体加强剂的反馈是压倒性的。我们目前正在与我们目前为 2021 年供应疫苗的所有政府积极参与 2022 年的讨论和协议。”</blockquote></p><p> Last month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.</p><p><blockquote>上个月，该组织正式向美国食品和药物管理局申请紧急批准，允许其冠状病毒疫苗在未来几个月内用于青少年。</blockquote></p><p> Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.</p><p><blockquote>Moderna 本周早些时候向欧洲卫生当局提出了类似的请求，该公司表示，其 TeenCOVE 研究的后期数据“满足了其主要免疫原性终点，成功地将免疫反应与成人疫苗接种联系起来”，在 2,500 名参与者中，疫苗接种效力为 100%。 Moderna 表示，在疫苗两剂方案的第一剂后 14 天，有效率也达到了 93%。</blockquote></p><p> The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.</p><p><blockquote>该制药商要求 FDA 发布紧急使用授权 (EUA) 通知，允许其 mRNA-1273 用于 12 至 18 岁的儿童。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Surges to Record High as Vaccine Maker Added to S&P 500<blockquote>随着疫苗制造商加入标普500，Moderna 飙升至历史新高</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Surges to Record High as Vaccine Maker Added to S&P 500<blockquote>随着疫苗制造商加入标普500，Moderna 飙升至历史新高</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Thestreet</strong><span class=\"h-time small\">2021-07-16 22:26</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Moderna Inc. (<b>MRNA</b>) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.</p><p><blockquote>现代公司（<b>MRNA</b>) 该疫苗制造商有望下周进入标普500基准市场，周五股价飙升至历史新高。</blockquote></p><p> Moderna will replaceAlexion Pharmaceuticals (<b>ALXN</b>) in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (<b>AZN</b>) in December of last year.</p><p><blockquote>Moderna 将取代 Alexion Pharmaceuticals（<b>阿尔克辛</b>) 在全球最受密切关注的指数中，从 7 月 21 日星期三开盘开始，此前该指数被英国阿斯利康 (AstraZeneca) 以 390 亿美元收购 (<b>阿兹恩</b>）去年12月。</blockquote></p><p> Moderna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.</p><p><blockquote>Moderna 股价在周五早盘交易中上涨 6%，易手至每股 275.92 美元，创历史新高，这将使该股年初至今的涨幅扩大至约 165%，市值约为 1110 亿美元。</blockquote></p><p> Moderna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.</p><p><blockquote>Moderna 于 5 月 6 日公布的第一季度收益为每股 2.84 美元，好于预期，收入升至 19 亿美元。该制药商还将 2021 财年全年疫苗销售预测上调至 192 亿美元左右。</blockquote></p><p> Moderna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.</p><p><blockquote>Moderna 2021 年的基本计划是生产 8 亿剂信使 RNA 疫苗，该疫苗于去年 12 月获得 FDA 紧急批准，目标是“努力在 2021 年尽可能接近 10 亿剂，”班塞尔在 5 月初表示。</blockquote></p><p> \"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"</p><p><blockquote>“来自世界各国政府要求高效 mRNA 疫苗和变体加强剂的反馈是压倒性的。我们目前正在与我们目前为 2021 年供应疫苗的所有政府积极参与 2022 年的讨论和协议。”</blockquote></p><p> Last month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.</p><p><blockquote>上个月，该组织正式向美国食品和药物管理局申请紧急批准，允许其冠状病毒疫苗在未来几个月内用于青少年。</blockquote></p><p> Moderna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.</p><p><blockquote>Moderna 本周早些时候向欧洲卫生当局提出了类似的请求，该公司表示，其 TeenCOVE 研究的后期数据“满足了其主要免疫原性终点，成功地将免疫反应与成人疫苗接种联系起来”，在 2,500 名参与者中，疫苗接种效力为 100%。 Moderna 表示，在疫苗两剂方案的第一剂后 14 天，有效率也达到了 93%。</blockquote></p><p> The drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.</p><p><blockquote>该制药商要求 FDA 发布紧急使用授权 (EUA) 通知，允许其 mRNA-1273 用于 12 至 18 岁的儿童。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500\">Thestreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","MRNA":"Moderna, Inc."},"source_url":"https://www.thestreet.com/investing/moderna-surges-to-record-high-as-vaccine-maker-added-to-s-p-500","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168174427","content_text":"Moderna Inc. (MRNA) shares surged to a fresh record high Friday after the vaccine maker was tipped to enter the S&P 500 benchmark next week.\nModerna will replaceAlexion Pharmaceuticals (ALXN) in the world's most closely-tracked index, starting at the opening bell on Wednesday July 21, following its$39 billion takeover by Britain's AstraZeneca (AZN) in December of last year.\nModerna shares were marked 6% higher in early trading Friday to change hands at $275.92 each, an all-time high that would extend the stock's year-to-date gain to around 165% with a market value of around $111 billion.\nModerna postedstronger-than-expected first quarter earningsof $2.84 per share on May 6, with revenues rising to $1.9 billion. The drugmaker also boosted its full-year vaccine sales forecast to around $19.2 billion for the full 2021 financial year.\nModerna's base plan for 2021 is to produce 800 million doses of its messenger-RNA vaccine, which received emergency approval from the FDA in December of last year, with the aim of \"working hard to get as close to 1 billion doses in 2021 as we can,\" Bancel said in early May.\n\"The feedback from governments around the world requesting high-efficacy mRNA vaccines and variant boosters is overwhelming. We are now actively engaged in discussions and agreements for 2022 with all of the governments we are currently supplying for 2021.\"\nLast month, the groupformally asked the U.S. Food & Drug Administrationfor emergency approval to use allow its coronavirus vaccine to be administered to teenagers over the coming months.\nModerna, which filed a similar request with European health authorities earlier this week, said late-stage data from its TeenCOVE study \"met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination' with a vaccination efficacy of 100% among the 2,500 participants. A 93% efficacy rate was also noted 14 days after the first of the vaccine's two dose regiment, Moderna said.\nThe drugmaker is asking the FDA to issue an Emergency Use Authorization (EUA) notice that will allow its mRNA-1273 to be given to children between the ages of 12 and 18.","news_type":1,"symbols_score_info":{"AZN":0.9,"MRNA":0.9,"ALXN":0.9}},"isVote":1,"tweetType":1,"viewCount":2495,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/179044650"}
精彩评论